Compare Ginkgo Bioworks Holdings Inc (DNA) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Okta, Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Okta, Inc. trades at $155.4 (market cap $26.87B). The key difference: Okta, Inc. is far larger — about 45.5× Ginkgo Bioworks Holdings Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | OKTA | |
|---|---|---|
Market Cap | $590.53M | $26.87B |
Sector | Health | Technology |
52-Week High | $16.14 | $154.62 |
52-Week Low | $5.48 | $62.93 |
Enterprise Value | $627.78M | $24.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
OKTA trades at $139.53, up 0.65% today, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.91 exceeding the $0.853 estimate. Revenue grew to $2.61 billion in 2025, and net income turned positive at $28 million. Analyst sentiment is positive, with 72.55% recommending Buy.
The outlook is favorable due to AI-driven demand for cybersecurity, but high valuation multiples pose risks. The stock faces competition and must sustain growth to justify its P/E of 101.11. Upside exists if earnings continue to beat expectations, yet volatility from market sentiment shifts is a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
